Sector News

Icon buys MediMedia Pharma Solutions for $120 million

February 2, 2015
Life sciences
Ireland-based Icon is to acquire MediMedia Pharma Solutions for $120 million, creating “the industry’s leading integrated scientific communications and market access solution”.
 
The Yardley, Pennsylvania-based company is a division of MediMedia USA and is being sold by Vestar Capital Partners. The deal includes MediMedia Managed Markets and Complete Healthcare Communications. The former provides “strategic payer-validated market access solutions”, while the latter is an agency which works with medical affairs, commercial and brand development teams within life science companies.
 
Icon chief executive Ciaran Murray said “the need to demonstrate and communicate the value of new medicines is an important global healthcare trend” and the acquisition of MediMedia Pharma Solutions “deepens the expertise” of the company’s existing operations “and brings us outstanding scientific and medical communications capabilities”.
 
The deal comes days after Icon announced plans to create 200 new jobs as part of a new global innovation hub in Ireland, with the posts split between Dublin and Limerick.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach